Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS
Home/The Filing Wire/IRIDEX Corporation/ 10-Q

Quarterly Report · 10-Q

IRIDEX Corporation

IRIXNASDAQEQUITYCurrent

Quarterly Report

Filed Aug 18, 2026Accepted Aug 18, 2026, 4:54 PM EDTCIK 1006045Accession 0001193125-26-355641
View company →Permanent SEC source ↗
Share

Company context

Iridex Corporation is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, which include capital equipment and consumable probes for the ophthalmology market. The Company’s proprietary MicroPulse® technology delivers the therapeutic benefits of laser treatment while minimizing tissue damage, offering a safe, effective, and proven treatment for targeted sight-threatening eye conditions. Iridex’s current product line is used for the treatment of glaucoma and diabetic macular edema (DME) and other retinal diseases. Iridex products are sold in the United States through a direct sales force and internationally primarily through a network of independent distributors into more than 100 countries. For further information, visit the Iridex website at www.iridex.com.

Current securities

IRIXNASDAQ · EQUITY · Current

Recent company filings

  1. 4 filingSep 16, 2026
  2. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of ListingSep 2, 2026
  3. Results of Operations and Financial ConditionAug 18, 2026
  4. Submission of Matters to a Vote of Security Holders · Regulation FD DisclosureJul 16, 2026
  5. SCHEDULE 13D/A - filed by Novel Inspiration International Co., Ltd. regarding IRIDEX CORPJul 13, 2026

Registered securities in this filing

IRIDEX CORP · 10-Q · Filed 2026-08-18

As filed in this accession. Current/historical status below comes from the governed listing record; the cover itself remains exact to this filing.

Common Stock, par value $0.01 per share

Symbol
IRIX
Exchange
NASDAQ
Classification
COMMON
Status
Current
Filing context

Context: C_03f16650-1cfd-42aa-934b-d6e8fd00f229

Dimensions: Not supplied

Accession 000119312526355641 · 1 registered-security cover member

Read the exact SEC filing ↗

As-filed source

Primary evidence
As filedOpen full document ↗

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.